These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 29229605)

  • 21. Acquisition of resistance to vemurafenib leads to interleukin-10 production through an aberrant activation of Akt in a melanoma cell line.
    Inozume T; Tsunoda T; Morisaki T; Harada K; Shirasawa S; Kawamura T
    J Dermatol; 2018 Dec; 45(12):1434-1439. PubMed ID: 30222203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models.
    Smyth T; Paraiso KHT; Hearn K; Rodriguez-Lopez AM; Munck JM; Haarberg HE; Sondak VK; Thompson NT; Azab M; Lyons JF; Smalley KSM; Wallis NG
    Mol Cancer Ther; 2014 Dec; 13(12):2793-2804. PubMed ID: 25349308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation.
    Sandri S; Faião-Flores F; Tiago M; Pennacchi PC; Massaro RR; Alves-Fernandes DK; Berardinelli GN; Evangelista AF; de Lima Vazquez V; Reis RM; Maria-Engler SS
    Pharmacol Res; 2016 Sep; 111():523-533. PubMed ID: 27436149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Joint action of miR-126 and MAPK/PI3K inhibitors against metastatic melanoma.
    Pedini F; De Luca G; Felicetti F; Puglisi R; Boe A; Arasi MB; Fratini F; Mattia G; Spada M; Caporali S; Biffoni M; Giuliani A; Carè A; Felli N
    Mol Oncol; 2019 Sep; 13(9):1836-1854. PubMed ID: 31115969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
    Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
    Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HI-511 overcomes melanoma drug resistance
    Chang X; Zhang T; Wang Q; Rathore MG; Reddy K; Chen H; Shin SH; Ma WY; Bode AM; Dong Z
    Theranostics; 2020; 10(21):9721-9740. PubMed ID: 32863956
    [No Abstract]   [Full Text] [Related]  

  • 27. Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells.
    Zhao K; Lu Y; Chen Y; Cheng J; Zhang W
    Exp Cell Res; 2020 May; 390(2):111942. PubMed ID: 32173467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-Raf
    Wu PK; Hong SK; Park JI
    Cancer Lett; 2021 Apr; 502():25-33. PubMed ID: 33440231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.
    Xiao J; Egger ME; McMasters KM; Hao H
    BMC Cancer; 2018 Jun; 18(1):675. PubMed ID: 29929490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma.
    Fattore L; Campani V; Ruggiero CF; Salvati V; Liguoro D; Scotti L; Botti G; Ascierto PA; Mancini R; De Rosa G; Ciliberto G
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32178301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
    Brummer C; Faerber S; Bruss C; Blank C; Lacroix R; Haferkamp S; Herr W; Kreutz M; Renner K
    Cancer Lett; 2019 Feb; 442():453-463. PubMed ID: 30481565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.
    Feng JH; Nakagawa-Goto K; Lee KH; Shyur LF
    Mol Cancer Ther; 2016 Jun; 15(6):1163-76. PubMed ID: 27048951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAF
    Barceló C; Sisó P; Maiques O; García-Mulero S; Sanz-Pamplona R; Navaridas R; Megino C; Felip I; Urdanibia I; Eritja N; Soria X; Piulats JM; Penin RM; Dolcet X; Matías-Guiu X; Martí RM; Macià A
    J Invest Dermatol; 2020 Jun; 140(6):1253-1265. PubMed ID: 31877318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. USP18 enhances the resistance of BRAF-mutated melanoma cells to vemurafenib by stabilizing cGAS expression to induce cell autophagy.
    Ma ZR; Xiong QW; Cai SZ; Ding LT; Yin CH; Xia HL; Liu W; Dai S; Zhang Y; Zhu ZH; Huang ZJ; Wang Q; Yan XM
    Int Immunopharmacol; 2023 Sep; 122():110617. PubMed ID: 37478666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.
    Carroll MJ; Parent CR; Page D; Kreeger PK
    BMC Cancer; 2019 Oct; 19(1):1025. PubMed ID: 31672130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib).
    Kot M; Simiczyjew A; Wądzyńska J; Ziętek M; Matkowski R; Nowak D
    Cell Commun Signal; 2024 Aug; 22(1):410. PubMed ID: 39175042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-211 Loss Promotes Metabolic Vulnerability and BRAF Inhibitor Sensitivity in Melanoma.
    Sahoo A; Sahoo SK; Joshi P; Lee B; Perera RJ
    J Invest Dermatol; 2019 Jan; 139(1):167-176. PubMed ID: 30076926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The first small molecules capable of strongly suppressing proliferation of cancer cells harboring BRAF class I/II/III mutations.
    Choi SH; Shin I; Kim N; Nam Y; Sim T
    Biochem Biophys Res Commun; 2020 Nov; 532(2):315-320. PubMed ID: 32873393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.
    Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G
    Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
    Hartman ML; Sztiller-Sikorska M; Gajos-Michniewicz A; Czyz M
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.